Tyra Biosciences (NASDAQ: TYRA) holder files to sell 8,000 shares

Rhea-AI Filing Summary

Tyra Biosciences shareholder Daniel Bensen has filed a Form 144 indicating an intent to sell additional common shares. The notice covers 8,000 shares of common stock to be sold through Merrill Lynch, with an approximate sale date of 01/12/2026 on Nasdaq. These 8,000 shares were acquired on 08/28/2018 as founder shares directly from the issuer.

The filing also lists recent sales by Bensen over the prior three months. Transactions include 1,111 shares on 11/13/2025 for gross proceeds of 17,000, 110,228 shares on 11/14/2025 for 1,760,000, 20,072 shares on 11/17/2025 for 320,000, 75,633 shares on 11/18/2025 for 1,200,000, 49,956 shares on 11/19/2025 for 815,000, and 8,000 shares on 12/12/2025 for 180,000. The form includes the standard representation that the seller is not aware of undisclosed material adverse information about the company.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 2049 Century Park E, Ste 1200 Los Angeles CA 90067	8000	232000	53372098	01/12/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/28/2018	Founders shares	Issuer			8000	08/28/2018	n/a

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Daniel Bensen 2656 State St Carlsbad CA 92008	Common	11/13/2025	1111	17000
Daniel Bensen 2656 State St Carlsbad CA 92008	Common	11/14/2025	110228	1760000
Daniel Bensen 2656 State St Carlsbad CA 92008	Common	11/17/2025	20072	320000
Daniel Bensen 2656 State St Carlsbad CA 92008	Common	11/18/2025	75633	1200000
Daniel Bensen 2656 State St Carlsbad CA 92008	Common	11/19/2025	49956	815000
Daniel Bensen 2656 State St Carlsbad CA 92008	Common	12/12/2025	8000	180000

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the TYRA Form 144 filing by Daniel Bensen disclose?

The filing shows that Daniel Bensen has given notice of his intent to sell 8,000 shares of Tyra Biosciences common stock, to be sold through Merrill Lynch on or around 01/12/2026 on Nasdaq.

How many TYRA shares is Daniel Bensen planning to sell in this notice?

Bensen plans to sell 8,000 shares of Tyra Biosciences common stock, according to the Form 144 securities information table.

How and where will the TYRA shares in this Form 144 be sold?

The notice lists Merrill Lynch as broker, with an approximate sale date of 01/12/2026, and names Nasdaq as the securities exchange for the planned sale.

When and how did Daniel Bensen acquire the TYRA shares being sold?

The 8,000 shares covered by this notice were acquired on 08/28/2018 as founders shares from the issuer, with the date of payment also listed as 08/28/2018 and the nature of payment noted as n/a.

What TYRA stock sales has Daniel Bensen made in the last three months?

The filing lists several sales of Tyra Biosciences common stock in the prior three months, including 110,228 shares on 11/14/2025 for gross proceeds of 1,760,000 and other trades on 11/13/2025, 11/17/2025, 11/18/2025, 11/19/2025, and 12/12/2025 with specified share amounts and proceeds.

Does the TYRA Form 144 include a statement about undisclosed information?

Yes. By signing, the seller represents that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed, as required by the form.